15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.9B | $479M | 98.2% | 21.6% | $749M | — | $713M |
| 2024 | $2.4B | $341M | 98.6% | 24.2% | $557M | — | $233M |
| 2023 | $1.9B | $250M | 97.9% | 13.3% | $362M | — | $251M |
| 2022 | $1.5B | $155M | 98.4% | 16.7% | $323M | — | $263M |
| 2021 | $1.1B | $90M | 98.7% | 9.0% | $233M | — | $341M |
| 2020 | $1.0B | $407M | 99.0% | 15.6% | $218M | — | $187M |
| 2019 | $788M | $37M | 0.0% | 9.2% | $132M | — | $112M |
| 2018 | $451M | $21M | 98.9% | 8.2% | $77M | — | $142M |
| 2017 | $162M | -$143M | 99.2% | -81.3% | -$101M | — | $255M |
| 2016 | $15M | -$141M | 100.0% | -982.5% | -$110M | — | $83M |
| 2015 | — | -$89M | — | — | — | — | $74M |
| 2014 | — | -$61M | — | — | — | — | $31M |
| 2013 | — | -$46M | — | — | -$30M | — | $45M |
| 2012 | — | $5M | — | — | -$36M | — | $64M |
| 2011 | — | $38M | — | — | -$1M | — | $50M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $815M | $198M | 98.3% | 23.7% | $137M | — | $267M |
| Dec '25 | $806M | $154M | 97.8% | 26.2% | $391M | — | $713M |
| Sep '25 | $795M | $210M | 98.2% | 30.1% | $214M | — | $340M |
| Jun '25 | $688M | $108M | 98.4% | 21.2% | $90M | — | $264M |
| Mar '25 | $573M | $8M | 98.4% | 4.1% | $54M | — | $194M |
| Dec '24 | $628M | $103M | 98.5% | 22.6% | $235M | — | $233M |
| Sep '24 | $622M | $130M | 98.7% | 29.5% | $150M | — | $349M |
| Jun '24 | $590M | $65M | 98.4% | 24.6% | $53M | — | $140M |
| Mar '24 | $515M | $43M | 98.5% | 19.3% | $119M | — | $396M |
| Dec '23 | $515M | $148M | 98.4% | 29.2% | $118M | — | $251M |
| Sep '23 | $499M | $83M | 97.8% | 28.3% | $204M | — | $294M |
| Jun '23 | $453M | $96M | 97.5% | 16.3% | $173M | — | $160M |
| Mar '23 | $420M | -$77M | 98.0% | -27.2% | -$134M | — | $104M |
| Dec '22 | $412M | $89M | 98.1% | 25.1% | $141M | — | $263M |
| Sep '22 | $388M | $69M | 98.4% | 22.6% | $101M | — | $212M |
| Jun '22 | $378M | -$17M | 98.7% | 14.5% | $129M | — | $163M |
| Mar '22 | $311M | $14M | 98.5% | 1.0% | -$48M | — | $270M |
| Dec '21 | $312M | -$7M | 98.7% | -11.6% | -$5M | — | $341M |
| Sep '21 | $296M | $23M | 98.6% | 15.0% | $56M | — | $311M |
| Jun '21 | $289M | $42M | 98.9% | 21.7% | $99M | — | $368M |
How the market has priced NBIX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Neurocrine Biosciences Inc's revenue has grown 22.3% per year, and net income grown 3.3% per year. These are computed facts, not advice.
As of FY2025, Neurocrine Biosciences Inc reported — of total debt against $713M of cash.
In FY2025, gross margin was 98.2%, operating margin 21.6%, and net margin 16.7%.
As of Jun '26, Neurocrine Biosciences Inc traded at a price-to-earnings ratio of about 34.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.